false Q3 0001604464 --12-31 2012-08-01 true true true true true true us-gaap:AccountingStandardsUpdate201602Member P6Y6M 0001604464 2020-01-01 2020-09-30 xbrli:shares 0001604464 2020-10-30 iso4217:USD 0001604464 2020-09-30 0001604464 2019-12-31 iso4217:USD xbrli:shares 0001604464 2020-07-01 2020-09-30 0001604464 2019-07-01 2019-09-30 0001604464 2019-01-01 2019-09-30 0001604464 us-gaap:CommonStockMember 2019-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001604464 us-gaap:RetainedEarningsMember 2019-12-31 0001604464 atra:AtTheMarketOfferingMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001604464 atra:AtTheMarketOfferingMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001604464 atra:AtTheMarketOfferingMember 2020-01-01 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001604464 2020-01-01 2020-03-31 0001604464 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001604464 us-gaap:RetainedEarningsMember 2020-03-31 0001604464 2020-03-31 0001604464 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001604464 2020-04-01 2020-06-30 0001604464 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001604464 us-gaap:CommonStockMember 2020-06-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001604464 us-gaap:RetainedEarningsMember 2020-06-30 0001604464 2020-06-30 0001604464 atra:AtTheMarketOfferingMember us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001604464 atra:AtTheMarketOfferingMember us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001604464 atra:AtTheMarketOfferingMember 2020-07-01 2020-09-30 0001604464 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001604464 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001604464 us-gaap:CommonStockMember 2020-09-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001604464 us-gaap:RetainedEarningsMember 2020-09-30 0001604464 atra:AtTheMarketOfferingMember us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001604464 atra:AtTheMarketOfferingMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001604464 us-gaap:CommonStockMember 2018-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001604464 us-gaap:RetainedEarningsMember 2018-12-31 0001604464 2018-12-31 0001604464 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001604464 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001604464 us-gaap:CommonStockMember srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2018-12-31 0001604464 us-gaap:AdditionalPaidInCapitalMember srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2018-12-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2018-12-31 0001604464 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2018-12-31 0001604464 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2018-12-31 0001604464 2019-01-01 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001604464 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-03-31 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001604464 us-gaap:RetainedEarningsMember 2019-03-31 0001604464 2019-03-31 0001604464 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001604464 2019-04-01 2019-06-30 0001604464 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001604464 us-gaap:CommonStockMember 2019-06-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001604464 us-gaap:RetainedEarningsMember 2019-06-30 0001604464 2019-06-30 0001604464 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001604464 us-gaap:AdditionalPaidInCapitalMember atra:AtTheMarketOfferingMember 2019-07-01 2019-09-30 0001604464 atra:AtTheMarketOfferingMember 2019-07-01 2019-09-30 0001604464 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001604464 us-gaap:CommonStockMember 2019-09-30 0001604464 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001604464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001604464 us-gaap:RetainedEarningsMember 2019-09-30 0001604464 2019-09-30 0001604464 us-gaap:AccountingStandardsUpdate201613Member 2020-09-30 0001604464 us-gaap:AccountingStandardsUpdate201815Member 2020-09-30 0001604464 us-gaap:AccountingStandardsUpdate201912Member 2020-09-30 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001604464 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001604464 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001604464 atra:EmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001604464 atra:EmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001604464 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001604464 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001604464 2019-01-01 2019-12-31 0001604464 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001604464 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001604464 us-gaap:EquipmentMember 2020-09-30 0001604464 us-gaap:EquipmentMember 2019-12-31 0001604464 us-gaap:MachineryAndEquipmentMember 2020-09-30 0001604464 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001604464 atra:ComputerEquipmentAndSoftwareMember 2020-09-30 0001604464 atra:ComputerEquipmentAndSoftwareMember 2019-12-31 0001604464 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001604464 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001604464 us-gaap:ConstructionInProgressMember 2020-09-30 0001604464 us-gaap:ConstructionInProgressMember 2019-12-31 0001604464 atra:MemorialSloanKetteringCancerCenterAgreementMember 2020-09-30 0001604464 atra:MemorialSloanKetteringCancerCenterAgreementMember 2019-01-01 2019-03-31 0001604464 atra:UnderwrittenPublicOfferingMember 2020-04-01 2020-06-30 0001604464 atra:UnderwrittenPublicOfferingMember 2020-06-30 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember 2020-06-30 0001604464 atra:UnderwrittenPublicOfferingMember srt:MaximumMember 2020-04-01 2020-06-30 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember 2019-07-18 2019-07-18 xbrli:pure 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember srt:MaximumMember 2019-07-18 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember us-gaap:WarrantMember srt:MinimumMember 2019-07-18 2019-07-18 0001604464 atra:UnderwrittenPublicOfferingMember atra:TwoThousandTwentyWarrantsMember 2020-09-30 0001604464 atra:UnderwrittenPublicOfferingMember atra:TwoThousandNineteenWarrantsMember 2019-07-31 0001604464 atra:UnderwrittenPublicOfferingMember atra:TwoThousandNineteenWarrantsMember 2020-09-30 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2019-02-25 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2020-02-28 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2019-02-25 2019-02-25 0001604464 atra:AtTheMarketOfferingMember atra:CowenAndCompanyLimitedLiabilityCompanyMember srt:MaximumMember 2020-02-28 2020-02-28 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-01-01 2020-09-30 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-07-01 2020-09-30 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember 2020-01-03 2020-01-03 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:AtTheMarketOfferingMember us-gaap:SubsequentEventMember 2020-10-02 2020-10-02 0001604464 atra:CowenAndCompanyLimitedLiabilityCompanyMember atra:TwoThousandTwentyAtTheMarketOfferingMember 2020-09-30 0001604464 us-gaap:RestrictedStockUnitsRSUMember atra:FromDateOfGrantMember 2020-01-01 2020-09-30 0001604464 srt:MinimumMember 2020-01-01 2020-09-30 0001604464 srt:MinimumMember atra:TenPercentShareHolderMember 2020-01-01 2020-09-30 0001604464 atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-09-30 0001604464 srt:MinimumMember atra:EmployeesAndNonEmployeesMember 2020-01-01 2020-09-30 0001604464 atra:EmployeesAndNonEmployeesMember srt:MaximumMember 2020-01-01 2020-09-30 0001604464 atra:TwoThousandAndFourteenEquityIncentivePlanMember 2020-09-30 0001604464 atra:InducementPlanMember 2020-09-30 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001604464 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001604464 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2019-12-31 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2020-01-01 2020-09-30 0001604464 atra:TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember 2020-09-30 0001604464 us-gaap:EmployeeStockOptionMember 2020-09-30 0001604464 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001604464 atra:TwoThousandEighteenInducementPlanMember 2020-09-30 0001604464 atra:TwoThousandFourteenEmployeeStockPurchasePlanMember 2020-09-30 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001604464 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001604464 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-36548

 

ATARA BIOTHERAPEUTICS, INC.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

 

46-0920988

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

611 Gateway Blvd., Suite 900

South San Francisco, CA

 

94080

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (650) 278-8930

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

 

ATRA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

  

Accelerated filer

 

Non-accelerated filer

 

  

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

The number of outstanding shares of the Registrant’s Common Stock as of October 30, 2020 was 77,714,302 shares.

 

 

 

 


 

ATARA BIOTHERAPEUTICS, INC.

INDEX

 

 

  

 

  

Page

PART I.

  

FINANCIAL INFORMATION

  

 

 

 

 

Item 1.

  

Financial Statements (Unaudited)

  

 

 

 

 

 

  

Condensed Consolidated Balance Sheets

  

3

 

 

 

 

  

Condensed Consolidated Statements of Operations and Comprehensive Loss

  

4

 

 

 

 

  

Condensed Consolidated Statements of Changes in Stockholders’ Equity

  

5

 

 

 

 

  

Condensed Consolidated Statements of Cash Flows

  

6

 

 

 

 

  

Notes to Condensed Consolidated Financial Statements

  

7

 

 

 

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

16

 

 

 

Item 3.

  

Quantitative and Qualitative Disclosures about Market Risk

  

26

 

 

 

Item 4.

  

Controls and Procedures

  

27

 

 

 

PART II.

  

OTHER INFORMATION

  

 

 

 

 

Item 1.

  

Legal Proceedings

  

28

 

 

 

Item 1A.

  

Risk Factors

  

28

 

 

 

Item 2.

  

Unregistered Sales of Equity Securities and Use of Proceeds

  

62

 

Item 3.

  

Defaults Upon Senior Securities

  

62

 

Item 4.

  

Mine Safety Disclosures

  

62

 

Item 5.

  

Other Information

  

62

 

Item 6.

  

Exhibits

  

63

 

 

 

  

Signatures

  

65

 

 

 

 

 

 

2


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except per share amounts)

 

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

62,620

 

 

$

74,317

 

Short-term investments

 

 

264,565

 

 

 

184,792

 

Restricted cash - short-term

 

 

194

 

 

 

194

 

Prepaid expenses and other current assets

 

 

12,053

 

 

 

13,689

 

Total current assets

 

 

339,432

 

 

 

272,992

 

Property and equipment, net

 

 

51,954

 

 

 

54,176

 

Operating lease assets

 

 

12,069

 

 

 

14,007

 

Restricted cash - long-term

 

 

1,200

 

 

 

1,200

 

Other assets

 

 

877

 

 

 

567

 

Total assets

 

$

405,532

 

 

$

342,942

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,190

 

 

$

7,963

 

Accrued compensation

 

 

16,710

 

 

 

14,706

 

Accrued research and development expenses

 

 

8,883

 

 

 

8,341

 

Other current liabilities

 

 

5,272

 

 

 

5,733

 

Total current liabilities

 

 

36,055

 

 

 

36,743

 

Operating lease liabilities - long-term

 

 

13,129

 

 

 

14,136

 

Other long-term liabilities

 

 

2,413

 

 

 

1,282

 

Total liabilities

 

 

51,597

 

 

 

52,161

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock—$0.0001 par value, 500,000 shares authorized as of September 30,

   2020 and December 31, 2019; 77,220 and 56,806 shares issued and outstanding

   as of September 30, 2020 and December 31, 2019, respectively

 

 

8

 

 

 

6

 

Additional paid-in capital

 

 

1,396,674

 

 

 

1,108,516

 

Accumulated other comprehensive income

 

 

527

 

 

 

220

 

Accumulated deficit

 

 

(1,043,274

)

 

 

(817,961

)

Total stockholders’ equity

 

 

353,935

 

 

 

290,781

 

Total liabilities and stockholders’ equity

 

$

405,532

 

 

$

342,942

 

 

 

See accompanying notes.

3


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

59,877

 

 

$

53,538

 

 

$

179,096

 

 

$

154,457

 

General and administrative

 

 

14,829

 

 

 

19,018

 

 

 

48,259

 

 

 

61,525

 

Total operating expenses

 

 

74,706

 

 

 

72,556

 

 

 

227,355

 

 

 

215,982

 

Loss from operations

 

 

(74,706

)

 

 

(72,556

)

 

 

(227,355

)

 

 

(215,982

)

Interest and other income, net

 

 

364

 

 

 

661

 

 

 

2,049

 

 

 

3,502

 

Loss before provision for income taxes

 

 

(74,342

)

 

 

(71,895

)

 

 

(225,306

)

 

 

(212,480

)

Provision for income taxes

 

 

6

 

 

 

 

 

 

7

 

 

 

 

Net loss

 

$

(74,348

)

 

$

(71,895

)

 

$

(225,313

)

 

$

(212,480

)

Other comprehensive gain:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale securities

 

 

(283

)

 

 

60

 

 

 

307

 

 

 

573

 

Comprehensive loss

 

$

(74,631

)

 

$

(71,835

)

 

$

(225,006

)

 

$

(211,907

)

Net loss per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$

(0.92

)

 

$

(1.31

)

 

$

(3.21

)

 

$

(4.32

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding used to calculate basic

   and diluted net loss per common share

 

 

81,176

 

 

 

54,920

 

 

 

70,170

 

 

 

49,176

 

 

See accompanying notes.

4


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

For the Nine Months Ended September 30, 2020

 

Shares

 

 

Amount

 

 

Capital

 

 

Income

 

 

Deficit

 

 

Equity

 

Balance as of December 31, 2019

 

 

56,806

 

 

$

6

 

 

$

1,108,516

 

 

$

220

 

 

$

(817,961

)

 

$

290,781

 

Issuance of common stock through ATM facilities, net of commissions

   and offering costs of $704

 

 

1,528

 

 

 

 

 

 

22,987

 

 

 

 

 

 

 

 

 

22,987

 

Exercise of pre-funded warrants

 

 

57

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSU settlements, net of shares withheld

 

 

455

 

 

 

 

 

 

(1,395

)

 

 

 

 

 

 

 

 

(1,395

)

Issuance of common stock pursuant to employee stock awards

 

 

94

 

 

 

 

 

 

1,330

 

 

 

 

 

 

 

 

 

1,330

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

12,644

 

 

 

 

 

 

 

 

 

12,644

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(73,509

)

 

 

(73,509

)

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

(16

)

Balance as of March 31, 2020

 

 

58,940

 

 

 

6

 

 

 

1,144,082

 

 

 

204

 

 

 

(891,470

)

 

 

252,822

 

Issuance of common stock and pre-funded warrants through underwritten

   offering, net of offering costs of $370

 

 

14,958

 

 

 

1

 

 

 

189,300

 

 

 

 

 

 

 

 

 

189,301

 

RSU settlements, net of shares withheld

 

 

219

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock pursuant to employee stock awards

 

 

191

 

 

 

 

 

 

1,904

 

 

 

 

 

 

 

 

 

1,904

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

13,948

 

 

 

 

 

 

 

 

 

13,948

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(77,456

)

 

 

(77,456

)

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

606

 

 

 

 

 

 

606

 

Balance as of June 30, 2020

 

 

74,308

 

 

 

7

 

 

 

1,349,234

 

 

 

810

 

 

 

(968,926

)

 

 

381,125

 

Issuance of common stock through ATM facilities, net of commissions

   and offering costs of $878

 

 

2,582

 

 

 

1

 

 

 

34,126

 

 

 

 

 

 

 

 

 

34,127

 

RSU settlements, net of shares withheld

 

 

316

 

 

 

 

 

 

(126

)

 

 

 

 

 

 

 

 

(126

)

Issuance of common stock pursuant to employee stock awards

 

 

14

 

 

 

 

 

 

185

 

 

 

 

 

 

 

 

 

185

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

13,255

 

 

 

 

 

 

 

 

 

13,255

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(74,348

)

 

 

(74,348

)

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

(283

)

 

 

 

 

 

(283

)

Balance as of September 30, 2020

 

 

77,220

 

 

$

8

 

 

$

1,396,674

 

 

$

527

 

 

$

(1,043,274

)

 

$

353,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

For the Nine Months Ended September 30, 2019

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balance as of December 31, 2018

 

 

45,951

 

 

$

5

 

 

$

866,541

 

 

$

(340

)

 

$

(527,349

)

 

$

338,857

 

Effect of the adoption of ASC topic 842 (Leases)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

364

 

 

 

364

 

Balance as of January 1, 2019

 

 

45,951

 

 

$

5

 

 

$

866,541

 

 

$

(340

)

 

$

(526,985

)

 

$

339,221

 

RSU settlements, net of shares withheld

 

 

197

 

 

 

 

 

 

(4,575

)

 

 

 

 

 

 

 

 

(4,575

)

Issuance of common stock pursuant to employee stock awards

 

 

159

 

 

 

 

 

 

2,898

 

 

 

 

 

 

 

 

 

2,898

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

12,269

 

 

 

 

 

 

 

 

 

12,269

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(66,257

)

 

 

(66,257

)

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

378

 

 

 

 

 

 

378

 

Balance as of March 31, 2019

 

 

46,307

 

 

 

5

 

 

 

877,133

 

 

 

38

 

 

 

(593,242

)

 

 

283,934

 

Issuance of common stock through ATM facilities, net of commissions

   and offering costs of $338

 

 

359

 

 

 

 

 

 

7,630

 

 

 

 

 

 

 

 

 

7,630

 

RSU settlements, net of shares withheld

 

 

120

 

 

 

 

 

 

(2,095

)

 

 

 

 

 

 

 

 

(2,095

)

Issuance of common stock pursuant to employee stock awards

 

 

97

 

 

 

 

 

 

1,802

 

 

 

 

 

 

 

 

 

1,802

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

15,201

 

 

 

 

 

 

 

 

 

15,201

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(74,328

)

 

 

(74,328

)

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

135

 

 

 

 

 

 

135

 

Balance as of June 30, 2019

 

 

46,883

 

 

 

5

 

 

 

899,671

 

 

 

173

 

 

 

(667,570

)

 

 

232,279

 

Issuance of common stock and pre-funded warrants through underwritten

   offering, net of offering costs of $288

 

 

6,872

 

 

 

 

 

 

140,711

 

 

 

 

 

 

 

 

 

140,711

 

Issuance of common stock through ATM facilities, net of

   commissions and offering costs of $155

 

 

327

 

 

 

 

 

 

5,000

 

 

 

 

 

 

 

 

 

5,000

 

RSU settlements, net of shares withheld

 

 

32

 

 

 

 

 

 

(25

)

 

 

 

 

 

 

 

 

(25

)

Issuance of common stock pursuant to employee stock awards

 

 

11

 

 

 

 

 

 

160

 

 

 

 

 

 

 

 

 

160

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

12,152

 

 

 

 

 

 

 

 

 

12,152

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(71,895

)

 

 

(71,895

)

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

60

 

 

 

 

 

 

60

 

Balance as of September 30, 2019

 

 

54,125

 

 

$

5

 

 

$

1,057,669

 

 

$

233

 

 

$

(739,465

)

 

$

318,442

 

 

See accompanying notes.

5


 

Atara Biotherapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(225,313

)

 

$

(212,480

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

39,847